State Street SPDR S&P Biotech ETF

State Street · Tracks S&P Biotechnology Select Industry Index · Inception Jan 31, 2006

Expense ratio
0.35%
35.0 bps
Net assets
$10.73B
TTM yield
0.37%
Last price
$156.22
as of Jul 15, 2026

Composite score

81 / 100
Cost 65

Based on a 0.35% expense ratio.

Liquidity 100

Based on $10.73B in net assets.

Concentration 85

Top-10 holdings represent 20.4% of net assets.

Tax efficiency 85

Healthcare base · ETF wrapper · 0.37% TTM yield.

The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).

Use XBI in our tools

Top holdings

156 total holdings · as of Mar 31, 2026
#HoldingWeight
1State Street Global Advisors8.01%
2Apellis Pharmaceuticals Inc1.83%
3Alkermes PLC1.45%
4Madrigal Pharmaceuticals Inc1.38%
5TG Therapeutics Inc1.35%
6Insmed Inc1.34%
7Scholar Rock Holding Corp1.30%
8Apogee Therapeutics Inc1.28%
9Protagonist Therapeutics Inc1.24%
10Summit Therapeutics Inc1.24%

Compare XBI with another fund

Or skim the closest-overlap funds below.

Similar ETFs by holdings overlap

Open XBI at a brokerage

Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.

Holdings sourced from SEC Form N-PORT-P (accession 0001410368-26-055543).